2024 ICD-10-CM Diagnosis Code C61

by

Malignant neoplasm of prostate

  • C61 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
  • The 2024 edition of ICD-10-CM C61 became effective on October 1, 2023.
  • This is the American ICD-10-CM version of C61 – other international versions of ICD-10 C61 may differ.

ICD-10-CM Coding Rules

  • C61 is applicable to male patients.

Use Additional

  • code, if applicable, to identify:
  • hormone sensitivity status (Z19.1-Z19.2)
  • rising PSA following treatment for malignant neoplasm of prostate (R97.21)

Type 1 Excludes

  • malignant neoplasm of seminal vesicle (C63.7)

The following code(s) above C61 contain annotation back-references

 that may be applicable to C61:

  • C00-D49  Neoplasms
  • C60-C63  Malignant neoplasms of male genital organs

Approximate Synonyms

  • Adenocarcinoma of prostate
  • Cancer of prostate with metastasis to eye
  • Cancer of the prostate
  • Cancer of the prostate with metastasis
  • Cancer of the prostate, adenocarcinoma
  • Cancer of, prostate, hormone refractory
  • Carcinoma of prostate
  • Hormone refractory prostate cancer
  • Metastasis from malignant tumor of prostate
  • Prostate cancer metastatic to eye
  • Recurrent prostate cancer

Clinical Information

  • A primary or metastatic malignant tumor involving the prostate gland. The vast majority are carcinomas.
  • The prostate is the gland below a man’s bladder that produces fluid for semen. Prostate cancer is common among older men. It is rare in men younger than 40. Risk factors for developing prostate cancer include being over 65 years of age, family history, being african-american, and some genetic changes.symptoms of prostate cancer may include
    • problems passing urine, such as pain, difficulty starting or stopping the stream, or dribbling
    • low back pain
    • pain with ejaculation
    your doctor will diagnose prostate cancer by feeling the prostate through the wall of the rectum or doing a blood test for prostate-specific antigen (psa). Other tests include ultrasound, x-rays, or a biopsy.treatment often depends on the stage of the cancer. How fast the cancer grows and how different it is from surrounding tissue helps determine the stage. Men with prostate cancer have many treatment options. The treatment that’s best for one man may not be best for another. The options include watchful waiting, surgery, radiation therapy, hormone therapy, and chemotherapy. You may have a combination of treatments. nih: national cancer institute

ICD-10-CM C61 is grouped within Diagnostic Related Group(s) (MS-DRG v41.0):

  • 715 Other male reproductive system o.r. Procedures for malignancy with cc/mcc
  • 716 Other male reproductive system o.r. Procedures for malignancy without cc/mcc
  • 722 Malignancy, male reproductive system with mcc
  • 723 Malignancy, male reproductive system with cc
  • 724 Malignancy, male reproductive system without cc/mcc

Convert C61 to ICD-9-CMCode History

  • 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
  • 2017 (effective 10/1/2016): No change
  • 2018 (effective 10/1/2017): No change
  • 2019 (effective 10/1/2018): No change
  • 2020 (effective 10/1/2019): No change
  • 2021 (effective 10/1/2020): No change
  • 2022 (effective 10/1/2021): No change
  • 2023 (effective 10/1/2022): No change
  • 2024 (effective 10/1/2023): No change

Code annotations containing back-references to C61:

Diagnosis Index entries containing back-references to C61: